Patents by Inventor Kasim A. Mookhtiar
Kasim A. Mookhtiar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220402927Abstract: The present disclosure relates to a series of tricyclic compounds, their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by adenosine receptor (AR) activity. The disclosure also relates to process of preparation of these tricyclic compounds of Formula I. These compounds are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by antagonism of the adenosine receptor. The disclosure also relates to the process of preparation of the tricyclic compounds, and to pharmaceutical compositions containing them.Type: ApplicationFiled: August 9, 2022Publication date: December 22, 2022Inventors: Sujay BASU, Sachin THORAT, Yogesh SHEJUL, Anil PANMAND, Meena PATEL, Goraksha KHOSE, Rajesh BONAGIRI, Dinesh BARAWKAR, Bheemashankar KULKARNI, Kasim MOOKHTIAR
-
Patent number: 11407758Abstract: The present disclosure relates to a series of tricyclic compounds, their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by adenosine receptor (AR) activity. The disclosure also relates to process of preparation of these tricyclic compounds of Formula I. These compounds are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by antagonism of the adenosine receptor. The disclosure also relates to the process of preparation of the tricyclic compounds, and to pharmaceutical compositions containing them. Formula (I) wherein D represents a tricyclic ring system selected from: Formula (II) or Formula (III).Type: GrantFiled: January 4, 2019Date of Patent: August 9, 2022Assignee: IMPETIS BIOSCIENCES LTD.Inventors: Sujay Basu, Sachin Thorat, Yogesh Shejul, Anil Panmand, Meena Patel, Goraksha Khose, Rajesh Bonagiri, Dinesh Barawkar, Bheemashankar Kulkarni, Kasim Mookhtiar
-
Patent number: 11098026Abstract: Fused bicyclic compounds are inhibitors of GPR91. The compounds, their stereoisomers, tautomers, prodrugs, polymorphs, solvates, pharmaceutically acceptable salts, and pharmaceutical compositions containing them are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of GPR91.Type: GrantFiled: March 13, 2018Date of Patent: August 24, 2021Assignee: IMPETIS BIOSCIENCES LIMITEDInventors: Nadim Shaikh, Mahesh Thakkar, Shailesh Shinde, Manoj Joshi, Keshav Naik, Amit Bhalerao, Mayur Mukim, Debnath Bhuniya, Bheemashankar Kulkarni, Kasim Mookhtiar
-
Publication number: 20210070764Abstract: The present disclosure relates to a series of tricyclic compounds, their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by adenosine receptor (AR) activity. The disclosure also relates to process of preparation of these tricyclic compounds of Formula I. These compounds are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by antagonism of the adenosine receptor. The disclosure also relates to the process of preparation of the tricyclic compounds, and to pharmaceutical compositions containing them. Formula (I) wherein D represents a tricyclic ring system selected from: Formula (II) or Formula (III).Type: ApplicationFiled: January 4, 2019Publication date: March 11, 2021Inventors: Sujay BASU, Sachin THORAT, Yogesh SHEJUL, Anil PANMAND, Meena PATEL,, Goraksha KHOSE, Rajesh BONAGIRI, Dinesh BARAWKAR, Bheemashankar KULKARNI, Kasim MOOKHTIAR
-
Publication number: 20200316077Abstract: The present disclosure discloses a pharmaceutical composition comprising compound of Formula I, Formula II, Formula III, Formula IV, and their pharmaceutically acceptable salts, analogs, tautomeric forms, stereoisomers, geometrical isomers, polymorphs, hydrates, solvates, metabolites, and prodrugs thereof, for the manufacture of a medicament for the treatment of a condition or disorder ameliorated by inhibition of the A2A/A2B receptor. It further discloses the use of the pharmaceutical composition of the present disclosure, for the preparation of a medicament for the treatment of a condition or disorder selected from prostate cancer, rectal cancer, renal cancer, ovarian cancer, endometrial cancer, thyroid cancer, pancreatic cancer, breast cancer, colon cancer, bladder cancer, brain cancer, glial cancer, melanoma cancer, pineal gland cancer, or lung cancer.Type: ApplicationFiled: December 19, 2018Publication date: October 8, 2020Inventors: Kasim MOOKHTIAR, Sujay BASU, Sreekanth ROUDURI, Ashwin MERU
-
Publication number: 20200087281Abstract: Fused bicyclic compounds are inhibitors of GPR91. The compounds, their stereoisomers, tautomers, prodrugs, polymorphs, solvates, pharmaceutically acceptable salts, and pharmaceutical compositions containing them are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of GPR91.Type: ApplicationFiled: March 13, 2018Publication date: March 19, 2020Inventors: Nadim SHAIKH, Mahesh THAKKAR, Shailesh SHINDE, Manoj JOSHI, Keshav NAIK, Amit BHALERAO, Mayur MUKIM, Debnath BHUNIYA, Bheemashankar KULKARNI, Kasim MOOKHTIAR
-
Patent number: 10435402Abstract: Substituted bicyclic compounds of formula (I), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, hydrates, N-oxides, co-crystals, pharmaceutically acceptable salts and pharmaceutical compositions containing them are disclosed, as well as processes for preparing and using the compounds. These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of retinoic acid-related orphan receptor gamma (RORy). Representative conditions include inflammatory and/or autoimmune disorder, rheumatoid arthritis, psoriasis, psoriatic arthritis, multiple sclerosis, inflammatory bowel disease, allergic diseases, asthma, COPD, cancer, cell proliferation, type 1 diabetes, myasthenia gravis, hematopoetic disfunction, systemic lupus, crythematosus or other disorders.Type: GrantFiled: January 8, 2016Date of Patent: October 8, 2019Assignee: Advinus Therapeutics LimitedInventors: Partha Mukhopadhyay, Yogesh Munot, Nadim Shaikh, Bheemashankar A. Kulkarni, Kasim Mookhtiar
-
Publication number: 20170362225Abstract: The present disclosure relates to a class of substituted bicyclic compounds of formula (I), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, hydrates, N-oxides, co-crystals, pharmaceutically acceptable salts and pharmaceutical compositions containing them. The disclosure also relates to the process of preparation of compounds of Formula (I). These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of retinoic acid-related orphan receptor gamma (ROR?) such as inflammatory and/or autoimmune disorder, rheumatoid arthritis, psoriasis, psoriatic arthritis, multiple sclerosis, inflammatory bowel disease, allergic diseases, asthma, COPD, cancer, cell proliferation, type 1 diabetes, myasthenia gravis, hematopoetic disfunction, systemic lupus, erythematosus or other disorders.Type: ApplicationFiled: January 8, 2016Publication date: December 21, 2017Inventors: Partha Mukhopadhyay, Yogesh Munot, Nadim Shaikh, Bheemashankar A. Kulkarni, Kasim Mookhtiar
-
Patent number: 9682953Abstract: The present disclosure relates to substituted amide compounds that are inhibitors of Fatty Acid Amide Hydrolase (FAAH), their stereoisomers, tautomers, prodrugs, polymorphs, solvates, pharmaceutically acceptable salts, and pharmaceutical compositions containing them.Type: GrantFiled: September 21, 2012Date of Patent: June 20, 2017Assignee: ADVINUS THERAPEUTICS LIMITEDInventors: Rajendra Kharul, Debnath Bhuniya, Kasim A. Mookhtiar, Umesh Singh, Atul Hazare, Satish Patil, Laxmikant Datrange, Mahesh Thakkar
-
Patent number: 9550793Abstract: The present disclosure relates to a series of spirocyclic compounds of formula (I), their stereoisomers, tautomers, prodrugs, pharmaceutically acceptable salts, polymorphs, solvates, hydrates, N-Oxides, Co crystals and formulations thereof. The disclosure also relates to process of preparation of these spirocyclic compounds. These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of acyl CoA diacyl glycerol acyltransferase 1 (DGAT1).Type: GrantFiled: October 1, 2013Date of Patent: January 24, 2017Assignee: Advinus Therapeutics LimitedInventors: Summon Koul, Debnath Bhuniya, Kasim Mookhtiar, Sandeep Bhosale, Suresh Kurhade, Keshav Naik, Ravikumar Velayutham, Videsh Salunkhe
-
Patent number: 9233983Abstract: The present disclosure provides hetero-bicyclic compounds of formula (I), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, hydrates, N-oxides, co-crystals, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by Bruton's tyrosine kinase (Btk) activity, The disclosure also relates to the process of preparation of compounds of Formula (I). These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of Bruton's tyrosine kinase (Btk), such as inflammatory and/or autoimmune disorder, cell proliferation, rheumatoid arthritis, psoriasis, psoriatic arthritis, transplant rejection, graft-versus-host disease, multiple sclerosis, inflammatory bowel disease, allergic diseases, asthma, type 1 diabetes, myasthenia gravis, hematopoetic disfunction, B-cell malignancies, systemic lupus, erythematosus or other disorders.Type: GrantFiled: October 8, 2014Date of Patent: January 12, 2016Assignee: ADVINUS THERAPEUTICS LIMITEDInventors: Mahesh Thakkar, Summon Koul, Debnath Bhuniya, Kasim Mookhtiar, Santosh Kurhade, Yogesh Munot, Tanaji Mengawade, Bheemashankar A. Kulkarni
-
Publication number: 20150218187Abstract: The present disclosure relates to a series of spirocyclic compounds of formula (I), their stereoisomers, tautomers, prodrugs, pharmaceutically acceptable salts, polymorphs, solvates, hydrates, N-Oxides, Co crystals and formulations thereof. The disclosure also relates to process of preparation of these spirocyclic compounds. These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of acyl CoA diacyl glycerol acyltransferase 1 (DGAT1).Type: ApplicationFiled: October 1, 2013Publication date: August 6, 2015Inventors: Summon Koul, Debnath Bhuniya, Kasim Mookhtiar, Sandeep Bhosale, Suresh Kurhade, Keshav Naik, Ravikumar Velayutham, Videsh Salunkhe
-
Publication number: 20150065464Abstract: The present disclosure relates to substituted amide compounds that are inhibitors of Fatty Acid Amide Hydrolase (FAAH), their stereoisomers, tautomers, prodrugs, polymorphs, solvates, pharmaceutically acceptable salts, and pharmaceutical compositions containing them.Type: ApplicationFiled: September 21, 2012Publication date: March 5, 2015Inventors: Rajendra Kharul, Debnath Bhuniya, Kasim A. Mookhtiar, Umesh Singh, Atul Hazare, Satish Patil, Laxmikant Datrange, Mahesh Thakkar
-
Publication number: 20150064196Abstract: The present disclosure provides hetero-bicyclic compounds of formula (I), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, hydrates, N-oxides, co-crystals, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by Bruton's tyrosine kinase (Btk) activity, The disclosure also relates to the process of preparation of compounds of Formula (I). These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of Bruton's tyrosine kinase (Btk), such as inflammatory and/or autoimmune disorder, cell proliferation, rheumatoid arthritis, psoriasis, psoriatic arthritis, transplant rejection, graft-versus-host disease, multiple sclerosis, inflammatory bowel disease, allergic diseases, asthma, type 1 diabetes, myasthenia gravis, hematopoetic disfunction, B-cell malignancies, systemic lupus, erythematosus or other disorders.Type: ApplicationFiled: October 8, 2014Publication date: March 5, 2015Inventors: Mahesh Thakkar, Summon Koul, Debnath Bhuniya, Kasim Mookhtiar, Santosh Kurhade, Yogesh Munot, Tanaji Mengawade, Bheemashankar A. Kulkarni
-
Patent number: 8940900Abstract: Compounds of the present disclosure are 2,2,2-tri-substituted acetamide derivatives of formula (I), its polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts and formulations thereof, useful as Glucokinase activator. Processes of their preparation are also described in the disclosure. The disclosure also describes method to characterize partial glucokinase activators.Type: GrantFiled: February 25, 2008Date of Patent: January 27, 2015Assignee: Advinus Therapeutics Private LimitedInventors: Kasim A. Mookhtiar, Debnath Bhuniya, Bhavesh Dave, Gobind S. Kapkoti, Sujay Basu, Anita Chugh, Siddhartha De, Venkata P. Palle
-
Patent number: 8501955Abstract: Acetamide derivatives, their stereoisomers, tautomers, prodrugs, pharmaceutically acceptable salts, polymorphs, solvates and formulations thereof for the prophylaxis, management, treatment, control of progression, or adjunct treatment of diseases and/or medical conditions where the activation of glucokinase would be beneficial, are disclosed. The disclosure also provides process of preparation of these acetamide derivatives.Type: GrantFiled: October 7, 2008Date of Patent: August 6, 2013Assignee: Advinus Therapeutics Private LimitedInventors: Debnath Bhuniya, Sandeep Bhausaheb Bhosale, Gobind Sing Kapkoti, Venkata Poornapragnacharyulu Palle, Siddhartha De, Kasim A. Mookhtiar, Bhavesh Dave, Anil Deshpande, Santosh Kurhade, Balasaheb Kobal, Keshav Naik, Sachin Kandalkar
-
Patent number: 8299115Abstract: Pyrrole-2-carboxamide derivatives, their polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts and formulations thereof, beneficial for prophylaxis, management, treatment, control of progression, or adjunct treatment of diseases and/or medical conditions where the activation of glucokinase would be beneficial, are disclosed. The disclosure also provides process of preparation of these pyrrole-2-carboxamides.Type: GrantFiled: June 5, 2008Date of Patent: October 30, 2012Inventors: Debnath Bhuniya, S. Gobind Kapkoti, S. Jayakumar Warrier, Gagan Kukrejka, N. Jagadeesh Mavinahalli, P. Venkata Palle, A. Kasim Mookhtiar
-
Publication number: 20100310493Abstract: Acetamide derivatives, their stereoisomers, tautomers, prodrugs, pharmaceutically acceptable salts, polymorphs, solvates and formulations thereof for the prophylaxis, management, treatment, control of progression, or adjunct treatment of diseases and/or medical conditions where the activation of glucokinase would be beneficial, are disclosed. The disclosure also provides process of preparation of these acetamide derivatives.Type: ApplicationFiled: October 7, 2008Publication date: December 9, 2010Applicant: ADVINUS THERAPEUTICS PRIVATE LIMITEDInventors: Debnath Bhuniya, Sandeep Bhausaheb Bhosale, Gobind Sing Kapkoti, Venkata Poornapragnacharyulu Palle, Siddhartha De, Kasim A. Mookhtiar, Bhavesh Dave, Anil Deshpande, Santosh Kurhade, Balasaheb Kobal, Keshav Naik, Sachin Kandalkar
-
Publication number: 20100292143Abstract: Pyrrole-2-carboxamide derivatives, their polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts and formulations thereof, beneficial for prophylaxis, management, treatment, control of progression, or adjunct treatment of diseases and/or medical conditions where the activation of glucokinase would be beneficial, are disclosed. The disclosure also provides process of preparation of these pyrrole-2-carboxamides.Type: ApplicationFiled: June 5, 2008Publication date: November 18, 2010Applicant: ADVINUS THERAPEUTICS PRIVATE LIMITEDInventors: Debnath Bhuniya, S. Gobind Kapkoti, S. Jayakumar Warrier, Gagan Kukrejka, N. Jagadeesh Mavinahalli, P. Venkata Palle, A. Kasim Mookhtiar
-
Publication number: 20100144772Abstract: Compounds of the present disclosure are 2,2,2-tri-substituted acetamide derivatives of formula (I), its polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts and formulations thereof, useful as Glucokinase activator. Processes of their preparation are also described in the disclosure. The disclosure also describes method to characterize partial glucokinase activators.Type: ApplicationFiled: February 25, 2008Publication date: June 10, 2010Applicant: ADVINUS THERAPEUTICS PRIVATE LIMITEDInventors: Kasim A. Mookhtiar, Debnath Bhuniya, Bhavesh Dave, Gobind S. Kapkoti, Sujay Basu, Anita Chugh, Siddhartha De, Venkata P. Palle